Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026
    Facebook X (Twitter) Instagram
    Iraq HeraldIraq Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Iraq HeraldIraq Herald
    Home » Federal lawsuit targets pharmacy benefit managers over insulin costs
    Health

    Federal lawsuit targets pharmacy benefit managers over insulin costs

    September 20, 20243 Mins Read

    MENA Newswire News Desk: – The U.S. Federal Trade Commission (FTC) has filed a lawsuit against the three largest pharmacy benefit managers (PBMs), accusing them of inflating insulin prices and increasing costs for millions of diabetes patients. The suit, filed Friday, targets CVS’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx. These PBMs are responsible for negotiating drug prices with manufacturers and managing which drugs are covered by insurance plans.

    Federal lawsuit targets pharmacy benefit managers over insulin costs

    According to the FTC, the PBMs artificially raised insulin prices by excluding lower-cost options from their formularies, favoring more expensive drugs with higher rebates from manufacturers. This practice has driven up the price of insulin for patients, with Eli Lilly’s Humalog insulin cited as an example. The drug’s price surged by over 1,200% between 1999 and 2017, from $21 to $274.

    FTC Deputy Director of Competition Rahul Rao emphasized that the lawsuit aims to dismantle the PBMs’ rebate system and bring about broader reforms in drug pricing. “The Big Three PBMs have profited at the expense of patients who rely on life-saving medications,” Rao said. “This lawsuit marks a crucial step toward restoring fair competition in the pharmaceutical market.”

    The FTC’s complaint also highlights the role of the PBMs’ affiliated group purchasing organizations – Zinc Health Services, Ascent Health Services, and Emisar Pharma Services in perpetuating the inflated prices. The FTC claims these organizations played a key role in maintaining high prices by creating a system that prioritized higher rebates over affordable drug options.

    While the lawsuit focuses on insulin, FTC officials noted that their goal is to overhaul drug pricing practices across the pharmaceutical industry. Anonymously, one FTC official suggested that the rebate system distorts the market by making rebates a determining factor in which drugs are included in insurance plans.

    Pharmaceutical companies and PBMs have been locked in a blame game over who is responsible for the rising cost of insulin. CVS and Express Scripts issued statements defending their practices, claiming that the FTC’s actions could lead to higher costs for patients. CVS added that its customers typically pay less than $25 per insulin dose, while Cigna’s Express Scripts called the lawsuit a politically motivated move that ignores the complex realities of drug pricing.

    Friday’s legal action stems from a two-year investigation into PBMs and insulin manufacturers. Although drug companies are not named in this case, the FTC has warned manufacturers that they could face future lawsuits over similar practices. The FTC’s move is part of the Biden administration’s broader efforts to combat rising healthcare costs, especially in the pharmaceutical sector. As insulin remains critical for millions of Americans, the lawsuit underscores the high-stakes battle over drug prices in the U.S.

    Share. Facebook Twitter Pinterest LinkedIn Telegram Reddit Email

    Related Posts

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    WHO reports 67 yellow fever cases in nine African countries

    November 7, 2026

    Bangladesh dengue deaths reach 418 after deadliest month of 2026

    November 2, 2026

    DR Congo Ebola death toll climbs to 5,340 as cases reach 10,351

    November 2, 2026
    Editor's Pick

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    Chip boom lifts South Korea into $1 trillion export club

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026
    © 2026 Iraq Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.